Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial
ContributorsCsaki Huttner, Angela; Hatz, Christoph; van den Dobbelsteen, Germie; Abbanat, Darren; Hornacek, Alena; Frölich, Rahel; Dreyer, Anita M; Martin, Patricia; Davies, Todd; Fae, Kellen; van den Nieuwenhof, Ingrid; Thoelen, Stefan; de Vallière, Serge; Kuhn, Anette; Bernasconi, Enos; Viereck, Volker; Kavvadias, Tilemachos; Kling, Kerstin; Ryu, Gloria; Hülder, Tanja; Gröger, Sabine; Scheiner, David; Alaimo, Cristina; Harbarth, Stéphan Juergen
Published inThe Lancet Infectious Diseases, vol. 17, no. 5, p. 528-537
Publication date2017
Abstract
Keywords
- Adult
- Aged
- Escherichia coli Vaccines/administration & dosage/therapeutic use
- Extraintestinal Pathogenic Escherichia coli/isolation & purification
- Female
- Humans
- Immunogenicity, Vaccine
- Middle Aged
- Single-Blind Method
- Treatment Outcome
- Urinary Tract Infections/prevention & control
- Vaccination/methods
Affiliation
Citation (ISO format)
CSAKI HUTTNER, Angela et al. Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. In: The Lancet Infectious Diseases, 2017, vol. 17, n° 5, p. 528–537. doi: 10.1016/S1473-3099(17)30108-1
Main files (1)
Article (Published version)
Identifiers
- PID : unige:99034
- DOI : 10.1016/S1473-3099(17)30108-1
- PMID : 28238601
ISSN of the journal1473-3099
